Associate Professor, Clinical Medicine & Public Health
An associate professor with 14+ years in clinical medicine and epidemiology, spanning randomized controlled trials, population cohort studies, and health policy research. Has prepared manuscripts for and served as an informal pre-submission reviewer targeting NEJM, JAMA, BMJ, and The Lancet. Brings specific experience with the framing requirements for clinical trial manuscripts, CONSORT compliance, statistical reporting standards at top clinical journals, and the particular standards for global health submissions to The Lancet.
Journals reviewed for:
NEJM, JAMA, BMJ, The Lancet, Lancet Oncology
Research published in:
Published in NEJM, JAMA, BMJ, and The Lancet
Gut reports some editorial metrics but does not publish a fully stable official acceptance rate. The better submission question is whether the study delivers GI research with population-level or practice-changing significance.
A package-readiness guide to submitting to Biomedicines (MDPI): mechanism-and-translation fit, the SuSy portal, pre-check screening, single-blind review, and the CHF 2,600 APC.
How to write a point-by-point response to reviewers for Clinical Infectious Diseases, where the clinical-significance and generalizability bar carries into the rebuttal and CID tells you not to lengthen the manuscript.
A package-readiness guide to submitting to Diagnostics (MDPI): section-scope fit, the SuSy portal, the editorial pre-check, single-blind review, STARD/TRIPOD reporting, and the CHF 2,600 APC.
How to write a point-by-point response to reviewers for JAMA Oncology, where a separate statistical editor reviews your analysis, reporting checklists are enforced, and clinical-practice claims have to match the evidence.
A package-readiness guide to submitting to the Journal of Clinical Medicine (MDPI): clinical-scope fit, the SuSy portal, editorial pre-check, single-blind review, reporting-guideline compliance, and the CHF 2,600 APC.
Paper rejected from Clinical Infectious Diseases? 7 alternative journals by fit, scope, and review speed, plus the IDSA transfer route to OFID.
Paper rejected from European Respiratory Journal? 7 alternative journals by fit, scope, review speed, and the in-family ERJ Open Research route.
Paper rejected from JACC? 7 alternative cardiology journals by fit, scope, review speed, and APC, plus the in-family JACC transfer route.
Paper rejected from PLOS Medicine? 7 alternative journals by fit, selectivity, review speed, and APC, plus the PLOS portfolio transfer route.
How to avoid desk rejection at NEJM: prove broad clinical consequence, hard endpoints, and study authority strong enough for general medicine.
A practical Journal of Clinical Investigation submission guide focused on translational fit, disease-mechanism strength, and what must already be obvious before you submit.
A package-readiness guide to JAMA covering manuscript shape, Key Points, structured abstract, and general-medicine fit before upload.
Write a BMC Medicine response to reviewers that survives open peer review, with a copyable rebuttal template, tone fixes, and checklist tips.
Pre-submission and post-decision rebuttal guide for BMJ Open authors, grounded in pre-submission reviews on BMJ Open-targeted manuscripts.
A pre-submission and post-decision rebuttal guide for The BMJ. Grounded in pre-submission reviews on The BMJ-targeted clinical manuscripts and The BMJ's public author resources.
What a Clinical Psychology Review cover letter must say for a review or meta-analysis. Template, PRISMA framing, declarations, and common mistakes.
Clinical Psychology Review response to reviewers: how to rebut PRISMA, search, and risk-of-bias comments on a review or meta-analysis revision.
The European Respiratory Journal cover letter is the first thing the ERS editor reads at the fit screen. Here is what it has to say about clinical significance and scope, which reporting and registration statements to flag, how to suggest reviewers, and a template you can adapt.
A pre-submission readiness check for BMC Medicine: the breadth-and-advance test the desk applies, the reporting-checklist and registration requirements that trigger fast returns, and a clear submit-or-wait verdict.
Clinical Psychology Review readiness check: is your systematic review or meta-analysis ready, with PRISMA, novelty, and desk-reject risk.
How to write a point-by-point response to reviewers for Nature Medicine, where statistical scrutiny and CONSORT-class reporting matter, and major revision means new data, not new wording.
How to write a point-by-point response to reviewers for PLOS Medicine, where a staff editor and Academic Editor co-decide, major revisions trigger statistical re-review, and the CONSORT/PRISMA/STROBE and data-availability bar follows you into the rebuttal.
Paper rejected from BMC Medicine? Six realistic next journals ranked by fit, plus the BMC transfer route and what to fix before you resubmit.
Rejected from Clinical Psychology Review? 6 review-friendly alternatives ranked by fit, scope, speed, and APC, plus what to fix before you resubmit.
If The Lancet sent your manuscript back as a major revision, here is what the decision means, your revision deadline, how the clinical reviewers and the statistical reviewer re-review, and how to write the point-by-point response that survives a second round.
If your JAMA submission shows With Editor in ScholarOne, the manuscript is in the editor-in-chief plus deputy editor triage, with in-house statistical review, before any referee is invited. Here is what that decision involves and when the wait is normal.
If BMC Medicine sent your manuscript back as a major revision, here is what the decision means, how the transparent peer-review reviewers re-review, and how to write the point-by-point response to reviewers that survives a second round.
If BMJ Open sent your manuscript back as a major revision, here is what the decision means under open peer review, your odds, the deadline, and how to write a response that holds up when reviewer reports are published.
If The BMJ sent your manuscript back as a major revision, here is what the decision means under open peer review, what your odds are, and how to write a response that survives the weekly manuscript committee.
If JAMA sent your manuscript back as a major revision, here is what the decision means, your roughly 60-day deadline, how clinical reviewers and the in-house statistical editors re-review, and how to write the point-by-point response that survives a second round.
If NEJM sent your manuscript back as a major revision, here is what the decision means, your revision deadline, how clinical reviewers and the in-house statistical reviewers re-review, and how to write the point-by-point response that survives a second round.
BMJ desk rejects ~70% of submissions within days. Verify these 10 items covering clinical practice impact, international relevance, and what editors evaluate in the first read.
NEJM desk rejects ~90% of submissions within 2 weeks. Before you submit, verify these 12 items covering clinical impact, trial registration, statistical rigor, and what editors screen for first.
Language editing fixes grammar. Pre-submission review fixes the framing, claim calibration, and editorial positioning that non-native English speakers struggle with most. Here is why you probably need both.
Manuscript readiness scoring evaluates whether your paper is ready for a specific journal before you submit. Here is how it works, what the dimensions mean, and how to use the results.
Most manuscript improvement advice is too generic to act on. This guide maps improvement to the six dimensions editors actually use during triage, with named failure patterns and a one-pass fix protocol for each.
Formatting checklists won't get your paper through triage. Editors screen for six things: journal fit, claim calibration, methods completeness, figure quality, citation integrity, and reporting compliance. Here is how to check each one before you submit.
Peer reviewers don't read your manuscript cover to cover. They form a provisional accept-or-reject judgment in the first 10 minutes, and the rest of the review largely confirms that initial read. The sequence differs by journal tier, and understanding it changes how you should structure your manuscript.
Most manuscript rejections fall into predictable, fixable categories. This page breaks down why papers fail at desk review versus peer review, what failure patterns look like by discipline, and what the data actually shows about rejection rates by stage.
Nature Reviews Drug Discovery does not accept unsolicited primary research. Here is what the commissioned model means and where drug discovery research papers actually belong.
Annals of Oncology limits Original Articles to 3,000 words with a 250-word structured abstract and up to 6 figures/tables combined. References use Vancouver numbered style with square brackets, and CONSORT compliance is required for clinical trials.
Clinical Cancer Research limits Articles to 5,000 words with a 250-word structured abstract and up to 7 figures. A mandatory 150-word Translational Relevance statement is unique to this journal, and references use AACR numbered style with parenthetical citations.
eLife formatting guide. Word limits, figure specs, reference format, LaTeX vs Word, and journal-specific formatting quirks you need to know.
Gastroenterology formatting guide. Word limits, figure specs, reference format, LaTeX vs Word, and journal-specific formatting quirks you need to know.
JAMA formatting guide. Word limits, figure specs, reference format, LaTeX vs Word, and journal-specific formatting quirks you need to know.
JAMA Oncology formatting guide. Word limits, figure specs, reference format, LaTeX vs Word, and journal-specific formatting quirks you need to know.
Your paper was rejected. Before resubmitting unchanged to the next journal, here is how to identify the real rejection cause, fix it, and avoid losing another 3 to 6 months in a preventable rejection cycle.
A practical PLOS Medicine submission process guide covering the two-stage submission workflow, editorial screening, peer review stages, and what each decision means.
Journal submissions surged dramatically in late 2025. Desk rejection rates are rising. Review times are stretching. Here is what is happening, why, and how to adapt your submission strategy.
Nature Medicine desk-rejects 70-80% of submissions. The gate is not scientific rigor - it is translational importance. Here is how to test whether your paper clears it before the editor decides.
Desk rejection costs more than a setback. The real price includes 3 to 6 months lost, APC exposure averaging $1,626, and compounding career impact for early-career researchers.
30 to 70% of manuscripts are desk rejected without ever reaching peer review. Here is how to avoid it at any journal, from PLOS ONE to Nature.
If your American Journal of Psychiatry manuscript shows Under Review, here is what the editor and reviewers are likely doing and when to follow up.
If your Environmental Health Perspectives manuscript shows Under Review, here is what the editor and reviewers are likely doing and when to follow up.
If your New England Journal of Medicine manuscript shows Under Review, here is what the editor and reviewers are likely doing and when to follow up.
If your Nutrients manuscript shows Under Review, here is what MDPI and SuSy are likely doing and when to follow up.
A practical NEJM Evidence submission guide for authors deciding whether the manuscript truly belongs in a methods-conscious clinical-evidence journal from NEJM Group.
BMC Medicine submission process: portal steps, editorial screening, reporting checks, APC, and what to tighten before upload.
A practical PLOS Medicine submission guide covering the initial submission process, global health framing, reporting requirements, and what must be true before your paper enters review.
If your Allergy manuscript shows Under Review, here is what the editor and reviewers are likely doing and when to follow up.
If your Clinical Gastroenterology and Hepatology manuscript shows Under Review, here is what the editor and reviewers are likely doing and when to follow up.
If your Clinical Psychology Review manuscript shows Under Review, here is what the editor and reviewers are likely doing and when to follow up.
If your Diabetologia manuscript shows Under Review, here is what the editor and reviewers are likely doing and when to follow up.
If your Endoscopy manuscript shows Under Review, here is what the editor and reviewers are likely doing and when to follow up.
If your Journal of Clinical Investigation manuscript shows Under Review, here is what the editor and reviewers are likely doing and when to follow up.
If your The Lancet Infectious Diseases manuscript shows Under Review, here is what the editor and reviewers are likely doing and when to follow up.
If your NEJM Evidence manuscript shows Under Review, here is what the editor and reviewers are likely doing and when to follow up.
A practical JCI Insight submission guide for authors deciding whether the manuscript is broad, disease-relevant, category-ready, and complete enough for the journal's editorial screen.
How to submit to Diabetes Care, what the portal asks for, what slows papers down, and what editors usually notice before review starts.
Lancet Infectious Diseases submission guide: Editorial Manager upload, reporting checklists, global relevance, and Lancet fit.
CGH submission guide: Editorial Manager upload, clinical relevance statement, GI study-design fit, and AGA journal routing.
What submitting to AJP actually requires: the Editor-in-Chief and Deputy Editors' editorial review, the 3,500-word Regular Article cap, the 250-word abstract, the 5-table-and-figure maximum, the 40-reference cap, the 9.7-week first-review round, and the absence of a hybrid OA APC at this APA Publishing flagship.
What submitting to Environmental Health Perspectives actually requires: the NIEHS-to-ACS Publications transition mid-2025, the Diamond-to-Gold open-access shift in 2027 with author costs waived through 2026, and the top environmental-health editorial culture.
BMC Medicine submission guide: CONSORT-reported trials with half the items showing 'see Methods' get extended methodology revision rounds.
A practical Endocrine Reviews submission guide for endocrinologists evaluating their proposed synthesis against the journal's invited model and clinical/translational scope.
A practical Clinical Microbiology Reviews (CMR) submission guide for clinical microbiologists evaluating their proposed synthesis against the journal's invited model.
A practical RBME submission guide for authors deciding whether their review is broad enough, critical enough, and complete enough for editorial screening.
A practical International Journal of Oral Science submission guide for authors deciding whether the paper is strong enough, broad enough, and complete enough for this selective oral-science journal.
This Nutrients submission guide helps authors decide whether the manuscript is genuinely a nutrition paper and whether the package is ready for a fast editorial screen.
A practical Pharmacology & Therapeutics submission guide for authors deciding whether the journal is even an available target for their review idea.
A practical Protein & Cell submission guide for authors deciding whether the manuscript is broad enough, mechanistically strong enough, and complete enough for editorial screening.
A practical Trends in Endocrinology & Metabolism submission guide for authors deciding whether the journal is the right editorial home for their review or opinion idea.
CPR submission guide: clinical psychology review with field-defining synthesis on therapeutic intervention.
A practical European Heart Journal submission guide covering package readiness, broad-cardiology fit, and what to tighten before upload.
A practical Accident Analysis and Prevention submission guide for transportation safety researchers evaluating their work against the journal's safety analysis bar.
A practical Implementation Science submission guide for implementation researchers evaluating their work against the journal's theory and rigor bar.
This BMJ submission guide helps authors decide whether the paper is broad enough, mature enough, and clear enough for a flagship general-medical screen.
This Gastroenterology submission guide helps authors decide whether a GI manuscript has enough clinical or translational significance for the AGA flagship.
Avoid desk rejection at CGH by proving immediate GI clinical utility, realistic generalizability, and a sharper clinical relevance case.
Avoid desk rejection at Clinical Psychology Review with a real review article, rigorous methods, clinical utility, and broad enough scope.
Avoid desk rejection at Endoscopy with stronger procedural consequence, more credible study design, and a clearer endoscopist-facing lesson.
Avoid desk rejection at IEEE RBME by submitting a critical review with broad BME value, clear article type, and a strong future-directions frame.
Avoid desk rejection at International Journal of Oral Science with broader oral-science fit and stronger mechanistic depth.
Avoid desk rejection at JCI Insight with stronger field advance, broader physician-scientist relevance, and cleaner translational logic.
Avoid desk rejection at Journal of Biomedical Science with stronger biomedical breadth, deeper mechanism, and clearer medical consequence.
Avoid desk rejection at JCI by proving a real medicine-facing advance, not just strong mechanism with speculative translational language.
A practical guide to the papers Gastroenterology rejects before review, and what to fix before submitting a GI flagship manuscript.
How to avoid desk rejection at BMJ: what editors screen for first, and how to frame a clinically important paper for a broad medical audience.
Circulation review time: cardiovascular research with practice-changing implications for working cardiologists.
If your BMC Medicine submission shows Under Review, here is what the BMC handling editor and associate editor are doing during each stage and when to follow up.
BMC Medicine is fast at the editorial front end, but reviewed papers still take months because the journal asks for broad clinical relevance.
A practical Kidney International submission guide for authors deciding whether the paper is strong enough, clinically relevant enough, and complete enough for this flagship nephrology journal.
BMJ Open is not mainly a speed journal. The useful submission question is whether the open-review, broad-medicine model fits your paper better than a tighter specialty venue.
Gut is often faster than many journals at its level, but the useful question is still fit. A quick desk answer does not change the flagship-GI bar.
A package-readiness guide to BMJ Open covering reporting discipline, transparency expectations, and what must be stable before submission.
A practical BMJ submission guide: how to judge fit, prepare the package, and avoid obvious editorial misses before you submit.
Gut submission guide: gastroenterology research with practice-changing implications for working gastroenterologists.
A practical Nature Medicine submission guide for authors deciding whether the manuscript is translationally strong enough, clinically relevant enough, and complete enough for the journal.
A practical NEJM submission guide for authors deciding whether the manuscript has the clinical consequence, breadth, and package quality NEJM expects.
If your JAMA submission shows Under Review, here is what the editor-in-chief, deputy editors, and associate editors are doing during each stage and when to follow up.
If your BMJ submission shows Under Review, here is what the BMJ editors and weekly manuscript committee are doing during each stage and when to follow up.
If your Lancet submission shows Under Review, here is what the in-house editors are doing during each stage and when to follow up.
If your Annals of Internal Medicine submission shows Under Review, here is what the ACP editors are doing during each stage and when to follow up.
If your Annals of Oncology submission shows Under Review, here is what ESMO editors are doing during each stage and when to follow up.
If your Clinical Cancer Research submission shows Under Review, here is what AACR editors are doing during each stage and when to follow up.
If your eLife submission shows Under Review, here is what eLife editors are doing during each stage and what the Reviewed Preprint model means for your paper.
If your JAMA Cardiology submission shows Under Review, here is what JAMA Network editors are doing during each stage and when to follow up.
If your JAMA Internal Medicine submission shows Under Review, here is what JAMA Network editors are doing during each stage and when to follow up.
If your JAMA Oncology submission shows Under Review, here is what JAMA Network editors are doing during each stage and when to follow up.
If your Lancet Oncology submission shows Under Review, here is what Lancet editors are doing during each stage and when to follow up.
Avoid desk rejection at Kidney International with stronger nephrology consequence, broader readership fit, and a cleaner kidney-disease signal.
Avoid desk rejection at Molecular Therapy with stronger platform relevance, cleaner translational support, and a clearer flagship-journal fit.
PLOS Medicine desk rejects roughly half of initial submissions within 2 weeks. Here is what editors actually screen for and how to avoid the most common triage failures.
How to avoid desk rejection at Lancet: global clinical relevance, study authority, and broad medical consequence.
How to avoid desk rejection at JAMA: breadth, endpoint strength, methods, and whether a study truly belongs in general medicine.
A practical NEJM submission process guide covering what happens after upload, what editors screen for first, and what to fix before you submit.
A workflow-focused BMJ Open submission process guide covering what happens after upload, how open review changes the process, and where papers stall.
A practical BMJ submission process guide: what the portal asks for, what editors decide first, and what authors should expect after upload.
Circulation accepts about 7% of original research submissions. What that selectivity means, where papers get filtered, and when transfer is smarter.
BMC Medicine time to first decision is 8-14 weeks median. Submission-to-decision data, status meanings, what reviewers check, and follow-up guidance.
BMJ Open time to first decision is 8-16 weeks. Median submission-to-decision data, what each manuscript status means, and when to follow up.
eLife and BMC Medicine both publish open-access biomedical work, but they ask different first-page questions about scientific contribution, public health relevance, and article format.
Gastroenterology and Hepatology overlap on liver, biliary, and GI-disease work, but they reward different first-page framing around GI-wide impact versus liver-disease specialization.
Nature Medicine and BMJ both publish clinical research, but Nature Medicine rewards translational human-health insight while BMJ rewards practical medical consequence.
Nature Medicine and JAMA are both elite medical journals, but Nature Medicine wants translational mechanism while JAMA wants broad clinical evidence.
Nature Medicine and NEJM are both elite medical journals, but Nature Medicine wants translational mechanism while NEJM wants decisive clinical consequence.
NEJM and BMJ both publish clinical research, but NEJM rewards decisive clinical consequence while BMJ rewards practice, policy, public health, and transparent clinical debate.
PLOS ONE and BMC Medicine are both open-access options, but PLOS ONE rewards technical validity while BMC Medicine asks for influential medical relevance.
Dentistry papers need pre-submission review that checks clinical relevance, reporting guidelines, methods, materials, oral health claims, and journal fit.
Diabetes research papers need pre-submission review that checks endpoints, statistics, clinical relevance, guidelines, equity, and journal fit.
Endocrinology papers need pre-submission review that checks hormone biology, clinical context, endpoints, guidelines, statistics, and journal fit.
Epidemiology papers need pre-submission review that tests design, confounding, bias, STROBE reporting, data transparency, and causal claim discipline.
Gastroenterology papers need pre-submission review that tests clinical relevance, reporting quality, endpoints, statistics, endoscopy evidence, and journal fit.
Global health papers need pre-submission review that checks equity, LMIC partnership, reporting, ethics, policy claims, and journal fit.
Health economics papers need pre-submission review that checks CHEERS, model assumptions, costs, utilities, uncertainty, and journal fit.
Health services research papers need pre-submission review that checks systems context, data, implementation, methods, reporting, and fit.
Hematology papers need pre-submission review that checks phenotype, endpoints, trial reporting, translational logic, safety, and journal fit.
Hepatology papers need pre-submission review that tests liver-specific endpoints, cohort design, biomarkers, reporting quality, and journal fit.
Implementation science papers need pre-submission review that checks framework use, strategy reporting, outcomes, context, and journal fit.
Medical education papers need pre-submission review that checks learner context, assessment validity, curriculum evidence, reporting, and fit.
Nephrology papers need pre-submission review that checks kidney phenotype, endpoints, mechanisms, reporting, statistics, and journal fit.
Nutrition papers need pre-submission review that checks diet exposure, intervention fidelity, biomarkers, reporting, conflicts, and journal fit.
Oral science papers need pre-submission review that tests oral-biology depth, clinical relevance, methods, reporting quality, and journal fit.
Psychiatry manuscripts need pre-submission review that tests clinical framing, construct clarity, outcomes, reporting, statistics, ethics, and journal fit.
Public health papers need pre-submission review that checks study design, reporting guidelines, equity, policy relevance, data, and claims.
Radiology manuscripts need pre-submission review that tests imaging evidence, reader design, AI reporting, figure quality, ethics, statistics, and journal fit.
Surgery papers need pre-submission review that checks study design, outcomes, follow-up, reporting guidelines, data sharing, and journal fit.
Scientific Reports and BMC Medicine are both open-access options, but Scientific Reports is broad science while BMC Medicine is general medicine and health.
JAMA desk rejects ~85% of submissions but decides fast (~14 days). Verify these 10 items covering clinical practice impact, statistical rigor, and the JAMA Network transfer option.
The Lancet desk rejects over 80% of submissions within 1-2 weeks. Verify these 10 items covering global health relevance, clinical significance, and what editors screen for first.
Your paper was rejected and you are about to resubmit to another journal. Here is when review before resubmission prevents another 3-6 month rejection cycle and when you can skip it.
Kidney International is one of the cleaner flagship-journal timing cases because official ISN materials publish concrete workflow numbers. The desk screen is fast. The real question is whether the paper deserves flagship nephrology review.
Clinical Gastroenterology and Hepatology impact factor is 12.0 with a 5-year JIF of 11.7. See rank, trend, and what the number means.
CGH exposes an unusually clear official timing dashboard, and it shows a quick editorial front end but a real multi-month path to acceptance.
Clinical Psychology Review impact factor is 12.2 with a 5-year JIF of 16.8. See rank, trend, and what the number means before submission.
Endoscopy impact factor is 12.8 with a 5-year JIF of 10.3. See rank, quartile, JCI, and what this number really means for gastroenterology authors.
Endoscopy does not publish a polished median dashboard, but official accepted-manuscript pages make the accepted-paper path visible enough to plan around.
European Heart Journal impact factor is 35.6 with a 5-year JIF of 34.4. See rank, trend, and what that means before submission.
Gastroenterology impact factor is 25.1 with a 5-year JIF of 26.9. See rank, trend, and what that number means before submission.
Avoid desk rejection at NEJM Evidence by proving real clinical-evidence value, not just a decent study under a strong brand.
Avoid desk rejection at Pharmacology & Therapeutics by treating it as an invitation-gated review venue, not a normal cold-submission journal.
Avoid desk rejection at Protein & Cell with stronger breadth, cleaner mechanism, and a more submission-ready first read.
Avoid desk rejection at TEM with a stronger review thesis, cleaner article type, and a sharper endocrinology or metabolism angle.
IEEE RBME impact factor is 12.0 with a 5-year JIF of 13.1. See rank, trend, and what it means before submission.
International Journal of Oral Science impact factor is 12.2 with a 5-year JIF of 13.6. See rank, trend, and what it means before submission.
International Journal of Oral Science does not publish a simple public median decision clock. The useful signals are the journal's explicit fast-screen posture, two-referee review model, and selective oral-science fit bar.
JAMA Oncology impact factor is 20.1 with a 5-year JIF of 24.7. See the rank, trend, and what that number means before submission.
Journal of Biomedical Science impact factor is 12.1 with a 5-year JIF of 12.0. See rank, trend, and what it means before submission.
Kidney International impact factor is 12.6 with a 5-year JIF of 13.7. See rank, trend, and what it means before submission.
Molecular Psychiatry impact factor is 10.1 with a 5-year JIF of 11.8. See the rank, trend, and what that number means before submission.
Molecular Therapy impact factor is 12.0 with a 5-year JIF of 12.4. See rank, trend, and what it means before submission.
Molecular Therapy's official public timeline points to a several-month path, even though small-sample community reports can look much faster.
Nutrients impact factor is 5.0 with a 5-year JIF of 6.0. See the rank, trend, and what that number means before submission.
Nutrients moves faster than many traditional nutrition journals, but the speed only helps if the paper is genuinely about nutrition and the compliance surface is already clean.
Pharmacology & Therapeutics impact factor is 12.5 with a 5-year JIF of 14.0. See rank, trend, and what it means before you pitch.
Protein & Cell impact factor is 12.8 with a 5-year JIF of 19.5. See rank, trend, and what it means before submission.
TEM impact factor is 12.6 with a 5-year JIF of 12.5. See rank, trend, and what it means before you pitch.
BMJ Open now reports a 27% acceptance rate on its journal statistics page. The real filter is still methodological soundness, transparent reporting, and broad medical relevance.
BMJ Open charges GBP 2,163 (~$2,850 USD) for gold open access. Open peer review, clinical focus, institutional deals. Full cost breakdown and comparisons.
Circulation APC is roughly $4,000-$5,000. AHA hybrid OA, coverage options, metrics context, and when the fee is worth paying.
Before you submit to Nature Medicine, verify these 10 items covering clinical significance, translational depth, study design adequacy, and the editorial standards that stop 70-80% of submissions.
A practical JACC fit verdict for authors deciding whether their study really belongs in the flagship cardiology journal rather than a specialty title.
The definitive guide to pre-submission manuscript review: what it is, what it costs across providers, when AI is enough vs when you need a human expert, and how to decide if it is worth it for your paper.
Is AJE worth $289 for pre-submission review? Here is what the service actually delivers based on their own documentation, what it misses, and when cheaper alternatives provide more actionable feedback.
Pre-submission review is not always the right choice. Here are the specific situations where you should skip it, when a free check is sufficient, and when the investment genuinely pays for itself.
There are now dozens of manuscript review services. Here is a practical decision framework that helps you choose based on what your paper actually needs, not on marketing.
Publishing your first academic paper is harder than your advisor told you. The mistakes first-time authors make are predictable, preventable, and often invisible until a reviewer points them out.
Pharmacology manuscripts need dose-response data, proper controls, in vivo validation, and clear therapeutic relevance. Here is what reviewers at top pharmacology journals expect.
A practical Nature Medicine submission process guide covering what happens after upload, what editors screen first, and how to interpret silence or delay.
A practical system for responding to reviewer comments without sounding defensive, skipping key points, or making the editor work harder than necessary.
BMC Medicine editors need a cover letter that does more than summarize the abstract. It has to explain why the paper belongs in a broad general-medicine journal and why the package is ready now.
BMC Medicine formatting problems are usually package problems: abstract structure, reporting checklists, reviewer suggestions, declarations, and clean file setup all have to line up.
BMJ formatting is not mainly visual style. It is a disciplined general-medical package with structured reporting, patient involvement, and clean transparency.
PLOS Medicine cover letters work when they explain why the study belongs in a global clinical and public-health journal, not just in a local medical context.
PLOS Medicine formatting problems are usually package-stage problems: understanding the format-free initial submission, preparing the full submission later, and keeping abstract, cover letter, and reporting files aligned.
PLOS Medicine is a journal where the first useful timing question is whether the editors think the paper matters beyond one health system, not just how quickly reviewers reply.
Science Translational Medicine is one of the clearest examples of a translational journal with a sharp desk filter. The journal can reject quickly, but the files that survive often enter a longer and more revision-heavy process.
Is Enago worth it for manuscript review? It depends on which Enago review tier you mean, what problem you are trying to solve, and whether you need broad support or a narrower submission-readiness answer.
Not sure what pre-submission review actually involves? Here is the step-by-step process from upload to revision, what you receive at each stage, and how long it takes.
Clinical trial manuscripts face the toughest editorial scrutiny in academic publishing. Here is what editors and reviewers check first, why CONSORT 2025 changes the requirements, and how to prepare before submission.
A practical Gut submission process guide: how the portal works, what editors are deciding early, and what usually weakens a submission before review.
A practical guide to the Frontiers in Microbiology submission process, including section routing, collaborative review, and common delays.
Systematic reviews and meta-analyses face unique rejection triggers that differ from original research. Here is what editors check first, what PRISMA 2020 requires, and how to prepare.
After rejection from Hepatology, Journal of Hepatology is the direct European counterpart with a higher IF. Gastroenterology and Gut cover GI-liver overlap, and Hepatology Communications provides a natural AASLD cascade.
After rejection from BMJ Open, consider PLOS ONE for methodologically sound work, BMC Public Health for epidemiology, JMIR for digital health, or BMC Medicine if your paper is stronger than you think.
Paper rejected from The BMJ? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Paper rejected from Circulation? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
After rejection from European Heart Journal, consider Circulation or JACC as direct competitors, EHJ sister journals for subspecialty work, or Heart and JAHA for solid mid-tier cardiovascular research.
After rejection from Gastroenterology, consider Gut for translational GI research, American Journal of Gastroenterology for clinical work, or Clinical Gastroenterology and Hepatology as the AGA companion cascade.
Paper rejected from Gut? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Paper rejected from JAMA? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Paper rejected from NEJM? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
A practical fit verdict for authors deciding whether their disease-mechanism manuscript is realistically strong enough for Journal of Clinical Investigation.
Kidney International Supplements operates on a supplement model, not a standard open-submission research journal. Before submitting, understand how the KDIGO process and ISN-organized issues work.
Most manuscript quality checks focus on grammar and formatting. Editors triage on six different dimensions: journal fit, claim calibration, methods completeness, figure quality, citation integrity, and reporting compliance. Here is how to self-assess each one before you submit.
Thesify is a well-built academic writing tool for students and graduate researchers. It handles argument structure, rubric-based feedback, and literature search. For journal-submission readiness at selective journals, it has real gaps.
Peer review criteria aren't the same across journals. At Nature and Cell, reviewers are gatekeeping significance. At PLOS ONE, they're checking soundness only. Here's what your target journal's reviewers are actually evaluating.
Nature Reviews Nephrology does not accept unsolicited primary research. Here is what the invitation model means for nephrology researchers and where primary research papers belong.
BMJ accepts about 7% of submissions. Here's what the number means, where the real filter sits, and when BMJ is a better fit than JAMA or The Lancet.
The BMJ is for oncology papers with broad clinical, policy, or systems consequences. JAMA Oncology is for top-tier oncology work whose real audience is still cancer medicine.
European Heart Journal is stronger for broad cardiovascular papers. Blood is stronger for hematology papers with real field-wide consequence across blood biology and disorders.
European Heart Journal is the better first target for broad cardiovascular papers. BMJ Open is stronger for sound, publishable work that values methodological credibility over flagship selectivity.
European Heart Journal is for top-tier cardiovascular papers. Journal of Clinical Oncology is for broad clinical-oncology papers with strong field-level consequence.
European Heart Journal is for top-tier cardiovascular papers. Lancet Oncology is for practice-changing oncology work with global relevance.
JAMA is for liver papers with broad clinical or policy consequence across medicine. Hepatology is for top-tier liver papers whose deepest value still belongs inside the field.
The Lancet is for infectious-disease papers that become broad clinical or global-health events. CID is for strong clinician-facing ID papers that still belong primarily to infectious disease.
The Lancet is for rare diabetes papers that become broad clinical events. Diabetes Care is for strong clinical diabetes papers with direct management and outcomes relevance.
The Lancet is for GI papers that become broad medical or global-health events. Gut is for top-tier gastroenterology papers with strong translational or clinical consequence.
This isn't really a prestige contest. It's a fit contest. NEJM is for cardiovascular papers that change practice across medicine. European Heart Journal is for top-tier cardiology papers that speak directly to the field.
JAMA impact factor is 55.0 (JCR 2024), CiteScore 30.8, SJR 5.352. Five-year JIF 64.7, Q1, rank 4/332.
BMC Medicine JIF 8.3 is the strongest open-access general medicine journal below the Big 4. Here's when it's the right target and when to aim higher or narrower.
NEJM accepts 5-6% of manuscripts and desk-rejects over 90%. The numbers matter, but the more useful question is whether your paper is broad and practice-changing enough to clear the desk.
The Lancet is commonly estimated to accept about 4-5% of submissions, with over 80% desk-rejected in 1-2 weeks. Here's what the stage-by-stage data looks like and what determines whether your paper clears each stage.
NEJM and The Lancet are both elite, but they are not interchangeable. The real question is which one fits your study type, audience, and geography.
A practical The Lancet submission process guide covering what happens after upload, what editors screen for first, and what to fix before you submit.
A workflow-focused JAMA submission process guide covering what happens after upload, how triage works, and where papers get redirected or delayed.
BMJ Open fits sound clinical work, protocols, and negative results. When a selective specialty journal is the better call.
A practical PLOS ONE verdict for authors deciding whether the journal is legitimate, what its editorial model actually means, and when it is the right fit.
Nature Medicine accepts ~7% of submissions and desk-rejects 70%. What editors require and how to prepare a competitive manuscript.
BMJ IF 42.7 (JCR 2024), Q1 rank 5/332. Five-year JIF 76.1 is pandemic-inflated. What BMJ actually publishes.
BMC Medicine IF dropped from 12.5 to 8.3 after COVID normalization. Five-year JIF 9.4 is the real baseline. Q1, $3,054 APC, PubMed-indexed OA.
PLOS Medicine impact factor is 9.9 (JCR 2024). Q1, rank 13/332 in Medicine. APC $5,300 with waivers. See the trend and submission guidance.
Circulation impact factor is 38.6. Five-year JIF is 35.9. Quartile: Q1. Category rank: 1/98.
Diabetes Care impact factor is 16.6. Five-year JIF 14.5, Q1, rank 6/191. See comparisons and what it means for authors.
Trends in Molecular Medicine impact factor is 13.8 with a 5-year JIF of 14.4. Q1, rank 4/195. Comparisons and what it means.
Clinical Infectious Diseases impact factor is 7.3. Five-year JIF 7.2, Q1, rank 8/137. See comparisons and submission guidance.
The Lancet's impact factor is 88.5 in the internal JCR 2024 reference table, but the useful submission question is fit. The number signals top-tier reach, not automatic fit for every strong clinical paper.
Compare Circulation Vs European Heart Journal: scope, selectivity, editorial fit, audience, and which manuscript belongs at each journal before.
BMJ doesn't just send your paper to academic experts. It also sends it to patient and public reviewers who read your work with completely different eyes. Your cover letter needs to speak to both audiences, and that changes how you frame everything.
European Heart Journal often tells authors relatively quickly whether a paper belongs in flagship cardiology, but the real submission question is cardiovascular consequence across practice, not just speed.
Lancet Oncology formatting walkthrough for oncology research. Word limit, figure rules, references, reviewer-list.
Nature Medicine formatting guide. Word limits, figure specs, reference format, LaTeX vs Word, and journal-specific formatting quirks you need to know.
NEJM formatting: NEJM editors enforce practice-changing-evidence threshold in the first 5 days.
European Heart Journal is the better first target for broad cardiovascular papers. Hepatology is stronger for liver-disease work with real mechanistic, translational, or clinical hepatology consequence.
Annals of Oncology is stronger for high-end clinical and translational oncology with a European feel. JCO is stronger for broad clinical oncology papers with practice-changing intent.
Annals of Oncology is stronger for top-tier clinical and translational oncology with a European perspective. Lancet Oncology is stronger for papers with clearer global practice-changing force.
The BMJ is for oncology papers with broad clinical, policy, or systems consequences. Annals of Oncology is for top-tier oncology work whose real audience is still cancer medicine.
The BMJ is for hematology papers with broad clinical, policy, or systems consequences. Blood is for flagship hematology work whose real audience is still the field.
The BMJ is for broad clinical or policy papers with strong general-medical consequences. BMJ Open is for methodologically sound medical research that wins on transparency, not prestige filtering.
BMJ is for oncology papers with broad clinical or policy consequences. Clinical Cancer Research is for translational oncology work whose main audience is still cancer medicine.
The BMJ is for infectious-disease papers with broad clinical, policy, or systems consequences. Clinical Infectious Diseases is for clinician-facing ID papers.
The BMJ is for diabetes papers with broad clinical, policy, or systems consequences. Diabetes Care is for diabetes research whose real audience is still diabetes practice.
BMJ is for cardiovascular papers with broad clinical, policy, or systems consequences. European Heart Journal is for flagship cardiology work whose real audience is the cardiovascular field.
The BMJ is for GI papers with broad clinical, policy, or systems consequences. Gastroenterology is for flagship digestive-disease work whose real audience is still GI.
The BMJ is for GI papers with broad clinical, policy, or systems consequences. Gut is for top-tier gastroenterology papers whose real audience is still digestive disease.
The BMJ is for liver papers with broad clinical, policy, or systems consequences. Hepatology is for flagship liver-disease work whose real audience is still hepatology.
The BMJ is for cancer papers with broad clinical, policy, or systems consequences. Journal of Clinical Oncology is for top-tier oncology work whose real audience is clinical oncology.
The BMJ is for oncology papers with broad clinical, policy, or systems consequences. Lancet Oncology is for practice-changing oncology work with global relevance.
European Heart Journal is for top-tier cardiovascular papers. Annals of Oncology is for top-tier oncology work with broad clinical or translational consequence.
European Heart Journal is stronger for broad cardiology papers. Clinical Cancer Research is stronger for translational oncology papers with real patient-facing consequence.
European Heart Journal is the better first target for cardiovascular papers with broad cardiology consequence. Clinical Infectious Diseases is stronger for clinically actionable ID papers.
European Heart Journal is the better first target for broad cardiovascular papers. Diabetes Care is stronger for diabetes-practice papers with clear clinical consequence.
European Heart Journal is the better first target for broad cardiovascular papers. Gastroenterology is stronger for flagship GI work that still lives inside digestive disease.
European Heart Journal is the better first target for cardiovascular papers with broad cardiology consequence. Gut is stronger for GI and hepatology work with translational depth.
European Heart Journal is for top-tier cardiovascular papers. JAMA Oncology is for broad oncology papers with strong clinical consequences.
JAMA is for hematology papers with broad clinical or policy relevance across medicine. Blood is for flagship hematology work whose real audience is the field itself.
JAMA is for broad clinical papers with strong general-medical consequences. BMJ Open is for medically relevant, transparently reported studies that win on soundness rather than prestige filtering.
JAMA is for oncology papers with broad clinical or policy consequences across medicine. Clinical Cancer Research is for translational oncology work whose real audience is still cancer medicine.
JAMA is for infectious-disease papers with broad clinical or policy consequences across medicine. CID is for strong clinician-facing ID papers whose real audience is still infectious disease.
JAMA is for diabetes papers with broad clinical or public-health consequence across medicine. Diabetes Care is for papers that are strongest inside diabetes management.
JAMA is for cardiovascular papers with broad clinical or public-health consequence. European Heart Journal is for top-tier cardiology papers whose real audience is the field itself.
JAMA is for GI papers with broad clinical or policy consequence across medicine. Gastroenterology is for flagship digestive-disease papers that still belong inside the field.
JAMA is for GI papers with broad clinical or policy consequence across medicine. Gut is for top-tier gastroenterology papers with strong translational or clinical consequence.
The Lancet is for papers that become broad medical or global-health events. BMJ Open is for methodologically sound medical research that wins on transparency, not prestige filtering.
The Lancet is for cardiology papers that become broad medical or global-health events. European Heart Journal is for top-tier cardiovascular papers whose natural readership is the cardiology field.
The Lancet is for digestive-disease papers that break into broad medicine. Gastroenterology is for elite GI papers whose real value still depends on specialist readership.
The Lancet is for liver papers that become broad clinical or global-health events. Hepatology is for top-tier liver papers whose deepest value still belongs inside hepatology.
NEJM and BMJ are both elite general medical journals, but they aren't interchangeable. NEJM wants definitive practice-changing evidence. BMJ is more receptive to policy, systems, and population-health relevance.
These journals aren't close substitutes. NEJM is for rare practice-changing medicine. BMJ Open is for sound clinical and public-health research reviewed under a more inclusive open-access model.
NEJM is for infectious-disease papers that change broad clinical medicine. Clinical Infectious Diseases is for strong, clinician-facing ID work that changes diagnosis, treatment, prevention, or stewardship.
NEJM is for rare diabetes papers that become broad clinical events. Diabetes Care is the stronger first target for many high-quality clinical diabetes papers with direct practice relevance.
NEJM is the play for GI papers that become broad medical events. Gastroenterology is the better first target for many top digestive-disease papers, especially when mechanistic depth and GI-specific context matter.
NEJM is for gastroenterology papers that change medicine broadly. Gut is for top-tier GI work with strong translational or clinical consequence, especially in microbiome, IBD, liver, and GI oncology.
NEJM is for liver papers that change broad clinical medicine. Hepatology is the stronger first target for many serious liver studies that are field-defining but still liver-specific.
If you're searching NEJM Evidence impact factor, the key point is JIF status and how committees in your field view this title.
NEJM desk-rejects more than 80% of submissions, often within 7 days. The cover letter is your first and sometimes only chance to make the case for why your paper belongs there.
JAMA receives 6,000+ manuscripts per year and publishes fewer than 5%. The cover letter is your argument for why your research belongs in the most-read general medical journal in the US.
JAMA's overall acceptance rate is around 5%, with over 80% desk-rejected before peer review. Here's what the numbers mean and what actually determines whether your paper clears each stage.
After reading 50 cover letters for journal submissions in a single week, the patterns were painfully obvious. Here's what stood out.
JCI is commonly estimated to accept about 10% of submissions. Desk rejection accounts for 60-70%. What the selectivity means for translational and clinical papers.
BMJ Open impact factor is 2.3 (JCR 2024). CiteScore 4.5, SJR 1.016. Q2 in JCR, Q1 in Scopus. See what the metrics mean for submissions.
JAMA and The Lancet are both elite flagship journals, but they reward different types of clinical importance. The right choice depends less on prestige and more on what kind of consequence your paper actually has.
Both are prestigious journals, but JCI leans clinical while Nature Medicine emphasizes translational mechanism. Learn which one matches your paper.
BMJ and The Lancet are both elite journals, but they are not interchangeable. One rewards practical clinical evidence with transparency, the other rewards broader international consequence.
Nature Medicine and The Lancet are both top-tier journals, but they serve different audiences. Learn when to submit to each one.
JAMA Cardiology JIF 14.1 is the JAMA Network's cardiovascular journal. Here's when it's the right target, how the JAMA transfer pipeline works, and how it compares to JACC, Circulation, and EHJ.
Science Translational Medicine impact factor is 14.6 (JCR 2024). Q1, rank 3/195 in Medicine Research. h-index 357.
Nature Medicine accepts about 7% of submissions. IF 50.0, bridging bench and bedside. Here's what the acceptance rate means and who gets published.
Blood is commonly estimated to accept about 15-20% of submissions. What the ASH flagship selects for and how the selectivity breaks down by paper type.
Gastroenterology can move quickly at the desk, but the real question is not just speed. It is whether the paper is broad and complete enough to survive flagship-GI review.
Hepatology usually tells you fairly quickly whether the paper is in range, but the real submission question is whether the manuscript has enough liver-specific weight to justify the full review cycle.
BMJ formatting guide. Word limits, figure specs, reference format, LaTeX vs Word, and journal-specific formatting quirks you need to know.
BMJ Open formatting guide. Word limits, figure specs, reference format, LaTeX vs Word, and journal-specific formatting quirks you need to know.
Clinical Infectious Diseases does not publish a strong official acceptance rate. The better submission question is whether the paper actually changes infectious-disease diagnosis, treatment, prevention, or management.
Diabetes Care does not publish a strong official acceptance rate. The better submission question is whether the study could change clinical diabetes management or ADA guideline recommendations.
European Heart Journal does not publish a strong official acceptance rate. The better submission question is whether the study is large-scale, clinically consequential, and positioned to influence ESC guidelines.
Gastroenterology does not publish a strong official acceptance rate. The better submission question is whether the study advances GI or liver science with clinical or mechanistic significance at the AGA flagship level.
Hepatology does not publish a strong official acceptance rate. The better submission question is whether the study advances liver science with the clinical or mechanistic significance the AASLD flagship demands.
NEJM's impact factor is high, but the real submission decision is fit. The number tells you the journal's tier, not whether a strong specialty paper will survive triage.
The Krebs cycle paper got rejected because the journal had too many letters in the queue. The Higgs boson paper was never reviewed. Here's what happened after: and what it means for yours.
Postdoc publications define your independent career trajectory. Here is when pre-submission review has the highest ROI for career-critical papers.
Our reviewers include researchers like this one who have published in and reviewed for top journals. Get a structured pre-submission review before you submit.